MICRONOR
LOE ApproachingNDAORAL-28TABLET
Approved
Jan 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MICRONOR by Johnson & Johnson is clinical pharmacology 1. First approved in 1973.
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MICRONOR is a progestin-only oral contraceptive (minipill) approved in 1973 that prevents conception through multiple mechanisms including ovulation suppression in ~50% of users, cervical mucus thickening, and endometrial alteration. It is indicated for contraception in women seeking a non-estrogen oral option. The drug requires strict daily adherence due to rapid serum clearance and short half-life.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential headcount rationalization and shift to generic defense or market exit strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY 1. Mode of Action ORTHO MICRONOR progestin-only oral contraceptives prevent conception by suppressing ovulation in approximately half of users, thickening the cervical mucus to inhibit sperm penetration, lowering the midcycle LH and FSH peaks, slowing the movement of the ovum…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MICRONOR careers are declining due to LOE approaching and moderate competitive pressure; roles focus on market maintenance, generic transition management, and regulatory compliance rather than growth. Career development opportunities are limited compared to newer products, making this assignment better suited to specialists managing mature assets or those transitioning within the contraceptive portfolio.
Worked on MICRONOR at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.